Part of the UT Health Science Center
The Cancer Therapy & Research Center is the answer for cancer
A Cancer Center designated by the National Cancer Institute
Open-Label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination with Docetaxel as Second-Line Treatment in Subjects with Non-Small Cell Lung Cancer (NSCLC) (CTMS# 14-2020)
The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with locally advanced or metastatic non-small cell lung cancer.
To enroll or if you have questions about participation
Type of Cancer Treated